Clinical trials: Dyspnea During Activity
Chronic Obstructive Pulmonary Disease
The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This study assessed the effect of QVA149 on patient-reported dyspnea in moderate to severe Chronic Obstructive Pulmonary Disease (COPD) patients.
- Trial name
- BLAZE (NCT01490125)
- Testing
- QVA149, Tiotropium, Salbutamol/albuterol
- Where
- 43 sites in Belgium, Canada and 3 more
- Volunteers
- 247 people
- Sponsor
- Novartis Pharmaceuticals